gil-c-shutterstock-com-4-1-merck
Gil C / Shutterstock.com
3 May 2016Americas

Gilead v Merck hepatitis C dispute rocked by new allegation

A judge assessing a patent dispute between Merck and Gilead centring on hepatitis C treatments has allowed Gilead to submit new evidence of jurors allegedly being misled.

Gilead was told to pay Merck $200 million in damages for infringement earlier this year.

The news comes after Gilead claimed that Philippe Durette, a former Merck scientist, allegedly lied under oath in the dispute, which centres on Gilead’s drugs Harvoni (ledipasvir/sofosbuvir) and Sovaldi (sofosbuvir).

According to Gilead, Durette misled jurors surrounding patents obtained for Merck covering the sofosbuvir compound, which is used to treat hepatitis C.

Gilead said Durette relied on an earlier patent developed by another drug maker, Pharmasset, before that company was acquired by Gilead in 2011, and did not make the discoveries through his own research.

In 2013, Gilead sued Merck at the US District Court for the Northern District of California. It said two Merck-owned patents, which centre on the sofosbuvir compound, should be declared invalid. Gilead said that the patents were not specific enough to cover its drugs.

Merck, which filed a counterclaim of infringement, had demanded $2 billion in damages and royalties related to sales, but was awarded $200 million in March this year.

Both sides had until yesterday, May 2, to submit more arguments in the case.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
29 March 2016   Gilead has been ordered to pay Merck $200 million in damages following a trial that found it had infringed patents covering hepatitis C treatments.
Americas
9 June 2016   A US court has overturned an earlier ruling in which Merck was awarded $200 million in damages for patent infringement after finding that the pharmaceutical company had engaged in misconduct.
Americas
20 July 2017   A California district court has awarded Gilead Sciences $13.8 million in attorneys’ fees in a patent dispute against Merck & Co, Merck Sharp & Dohme and Isis Pharmaceuticals.

More on this story

Americas
29 March 2016   Gilead has been ordered to pay Merck $200 million in damages following a trial that found it had infringed patents covering hepatitis C treatments.
Americas
9 June 2016   A US court has overturned an earlier ruling in which Merck was awarded $200 million in damages for patent infringement after finding that the pharmaceutical company had engaged in misconduct.
Americas
20 July 2017   A California district court has awarded Gilead Sciences $13.8 million in attorneys’ fees in a patent dispute against Merck & Co, Merck Sharp & Dohme and Isis Pharmaceuticals.

More on this story

Americas
29 March 2016   Gilead has been ordered to pay Merck $200 million in damages following a trial that found it had infringed patents covering hepatitis C treatments.
Americas
9 June 2016   A US court has overturned an earlier ruling in which Merck was awarded $200 million in damages for patent infringement after finding that the pharmaceutical company had engaged in misconduct.
Americas
20 July 2017   A California district court has awarded Gilead Sciences $13.8 million in attorneys’ fees in a patent dispute against Merck & Co, Merck Sharp & Dohme and Isis Pharmaceuticals.